NEW YORK, October 5, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com reviews the following Biotech equities: Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), PTC Therapeutics Inc. (NASDAQ: PTCT), Aratana Therapeutics Inc. (NASDAQ: PETX), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). According to a new report by Grand View Research, the global white biotechnology market is expected to grow at a CAGR of 10.2% from 2016 to 2024, while the biofuels segment is forecasted to grow at a CAGR of more than 9% over the same period. Download the free research reports on these stocks today:
Tustin, California headquartered Peregrine Pharmaceuticals Inc.'s stock finished Tuesday's session 2.00% lower at $0.43. A total volume of 1.36 million shares was traded, which was above their three months average volume of 1.06 million shares. The Company's shares have advanced 12.18% in the past month and 12.18% in the previous three months. The stock is trading 11.57% above its 50-day moving average. Additionally, shares of Peregrine Pharmaceuticals, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have a Relative Strength Index (RSI) of 61.46.
On September 27th, 2016, Peregrine Pharmaceuticals announced the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of multiple checkpoint targeting agents including anti-PD-1 and anti-LAG3 therapies in a model of triple negative breast cancer (TNBC). Data showed that eight of the ten (80%) animals receiving the preclinical bavituximab equivalent (ch1N11) combined with anti-PD-1 and anti-LAG3 therapies ("Triple Combination") experienced complete tumor regressions, whereas there were no animals (0/10) in the anti-PD-1 and anti-LAG3 combination treatment arm that had a complete regression. See our free and comprehensive research report on PPHM at:
On Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. recorded a trading volume of 1.14 million shares. The stock ended the session 0.22% lower at $13.33. The Company's shares have surged 68.52% in the last one month and 87.48% over the previous three months. The stock is trading 56.53% above its 50-day moving average and 11.62% above its 200-day moving average. Moreover, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 73.83.
On October 4th, 2016, PTC Therapeutics announced that the Proceedings of the National Academy of Sciences (PNAS) has published new results further validating Translarna's™ (ataluren) mechanism of action to promote readthrough of premature stop codons resulting from nonsense mutations in genetic disorders. The results reported in PNAS establish ataluren's ability to alter the protein production process at premature stop codons and to promote the insertion of specific amino acids and restore the production of a full-length functional protein. PTCT free research report PDF is just a click away at:
Shares in Leawood, Kansas headquartered Aratana Therapeutics Inc. closed the day 0.87% lower at $10.30. The stock recorded a trading volume of 1.08 million shares, which was higher than its three months average volume of 757,120 shares. The Company's shares have gained 16.91% in the last month, 56.53% in the previous three months, and 84.59% on an YTD basis. The stock is trading 16.70% above its 50-day moving average and 65.73% above its 200-day moving average. Additionally, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide, have an RSI of 64.42.
As per notes filed with the SEC on September 01st, 2016, Julia Stephanus provided Aratana Therapeutics on July 30th, 2016, with a notice to cure and contingent resignation of her employment agreement. On August 30th, 2016, Ms. Stephanus and the Company entered into a consulting and separation agreement, which provides for her continued employment as Chief Commercial Officer of the Company until September 30th, 2016 following which she agreed to serve as a commercial consultant to the Company.
On September 6th, 2016, research firm Lake Street resumed its 'Buy' rating on the Company's stock, issuing a target price of $15 per share. Sign up for your complimentary report on PETX at:
At the close, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. ended the day at $16.23, which was a slight decline of 0.79%. The stock recorded a trading volume of 459,400 shares. The Company's shares have advanced 4.37% in the last one month, 39.31% in the previous three months, and 74.33% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 14.69% and 55.06%, respectively. Furthermore, shares of Vanda Pharmaceuticals, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 56.80. Register for free on Stock-Callers.com and download the latest research report on VNDA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA